Wikimd logo


W8MD Diet | COVID-19 portal | Vitamin D | Vaccine | Keto

WikiMD is the world's largest medical encyclopedia with
13,672 pages, 4,140,291 edits & 38,373,481 views.

Free unbiased diet, health and wellness info!

Adrafinil

From WikiMD's free health, diet & wellness encyclopedia
Jump to navigation Jump to search


Dr Prab R Tumpati, MD

Editor-In-Chief: Prab R. Tumpati M.D.. Founder, WikiMD and W8MD Weight Loss, Sleep and MedSpa Centers. Dr. Tumpati is board certified physician practicing sleep medicine, obesity medicine, aesthetic medicine and internal medicine. Dr. Tumpati’s passion is prevention rather than cure. As a physician with fellowship training in Obesity Medicine, Dr. Tumpati has a unique approach to wellness, weight loss, aesthetics with a focus on prevention rather than cure. Dr. Tumpati believes in educating the public on the true science and art of medicine, nutrition, wellness and beauty.

WikiMD Resources for Adrafinil
Articles
Most recent articles on Adrafinil

Most cited articles on Adrafinil Review articles on Adrafinil

Articles on Adrafinil in N Eng J Med, Lancet, BMJ

Media
Powerpoint slides on Adrafinil

Images of Adrafinil Photos of Adrafinil

Podcasts & MP3s on Adrafinil Videos on Adrafinil

Evidence Based Medicine
Cochrane Collaboration on Adrafinil

Bandolier on Adrafinil TRIP on Adrafinil

Clinical Trials
Ongoing Trials on Adrafinil at Clinical Trials.gov

Trial results on Adrafinil Clinical Trials on Adrafinil at Google

Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Adrafinil

NICE Guidance on Adrafinil NHS PRODIGY Guidance

FDA on Adrafinil CDC on Adrafinil

Books
Books on Adrafinil
News
Adrafinil in the news

Be alerted to news on Adrafinil News trends on Adrafinil

Commentary
Blogs on Adrafinil
Definitions
Definitions of Adrafinil
Patient Resources / Community
Patient resources on Adrafinil

Discussion groups on Adrafinil Patient Handouts on Adrafinil

Directions to Hospitals Treating Adrafinil Risk calculators and risk factors for Adrafinil

Healthcare Provider Resources
Symptoms of Adrafinil

Causes & Risk Factors for Adrafinil Diagnostic studies for Adrafinil

Treatment of Adrafinil

Continuing Medical Education (CME)
CME Programs on Adrafinil
International / other languages

en Espanol en Francais

Business
Adrafinil in the Marketplace

Patents on Adrafinil

Experimental / Informatics
List of terms related to Adrafinil
Adrafinil
Adrafinil.svg
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • Unscheduled (US)
Pharmacokinetic data
Bioavailability80%
Metabolism75% Hepatic, Cyp?
Elimination half-life1 hour
ExcretionRenal
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC15H15NO3S
Molar mass289.351 g/mol g·mol−1
3D model (JSmol)
 ☒NcheckY (what is this?)  (verify)

Adrafinil (CRL-40028, Olmifon) is a mild central nervous system stimulant drug used to relieve excessive sleepiness and inattention. It is also used off-label by individuals wishing to avoid fatigue, such as night workers or others who need to stay awake and alert for long periods of time.

Adrafinil is a prodrug; it is primarily metabolized in vivo to modafinil, resulting in nearly identical pharmacological effects. Unlike modafinil, however, it takes time for the metabolite to accumulate to active levels in the bloodstream. Effects usually are apparent within 45–60 minutes when taken orally on an empty stomach.

Adrafinil does not currently have FDA approval and is thus unregulated in the United States. It was marketed in France and elsewhere in Europe under the trade name Olmifon until September 2011 when France's FDA equivalent reassessed the drug and withdrew marketing permission.

History

Adrafinil was discovered in the late 1970s by scientists working with the French pharmaceutical company Group Lafon. First offered in France in 1986 as an experimental treatment for narcolepsy, Lafon later developed modafinil, the primary metabolite of adrafinil. Modafinil possesses greater selective alpha-1 adrenergic activity than adrafinil, without many of adrafinil's common side-effects (stomach pain, skin irritation, anxiety and (with prolonged use) elevated liver enzymes).[1] This makes it important to monitor the liver of an individual using adrafinil for prolonged periods.

As of September 2011, Cephalon has discontinued the Olmifon product.

Legal status

Athletic doping

Adrafinil and its active metabolite modafinil were added to the list of substances prohibited for athletic competition according to World Anti-Doping Agency in 2004.[2]

United States

In the United States, adrafinil is currently unregulated. It has not been approved for any clinical uses by the U.S. Food and Drug Administration. Unlike modafinil, adrafinil is not classified as a controlled substance and does not fall under DEA jurisdiction; in particular, it is not illegal to possess without a prescription and can be imported privately by citizens.

Canada

In Canada adrafinil is unregulated and can be legally purchased within the country as a research chemical, or imported privately by citizens.

New Zealand

In 2005 a Medical Classification Committee in New Zealand recommended to MEDSAFE NZ that Adrafinil be classified as a prescription medicine.

"Adrafinil had been referred to the MCC for classification as a prescription medicine by the Medicines Control section of Medsafe following growing concern about increased imports and potential abuse of this substance as a party drug. Evidence of misuse was supplied in support of the request for classification.

Adrafinil is not scheduled in New Zealand but is chemically related to modafinil which is a prescription medicine taken orally for mental function impairment in the elderly.

All participants agreed that adrafinil should be classified as a prescription medicine."[3]

See also

References

  1. World Anti-Doping Agency - 2007 Prohibited List
  2. MCC Minutes Out of Session Meeting. Medsafe.govt.nz (2013-05-23). Retrieved on 2013-12-18.

External links

  • open access


Comprehensive list of medications or pharmaceutical drugs used in the United States with their NDC or national drug code, brand name, dosage, forms of administration etc. sorted alphabetically.

See also

External links

The following is the collection of detailed information and links to the National Institute of Health (NIH) comprehensive drug information portal and other reliable sources of information. Select the drug name below to show drug description, drug classification, other common drug names, and information on the reasons why prescribed, how medication should be used, and what possible side effects could occur.

Drug names

A • B • C • D • E • F • G • H • I • J • K • L • M • N • O • P • Q • R • S • T • U • V • W • X • Y • Z

Search for other drug names not listed above Portions of content adapted from Wikipedia's article on Adrafinil which is released under the CC BY-SA 3.0.

 

Adrafinil is part of WikiMD's free ^articles!

^Adrafinil (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP. Tele medicine available